a treatment that works even before the headaches start

Migraine could soon be under control before symptoms even appear. The latest scientific breakthrough reveals that early treatment could stop an attack before it actually starts. This approach could transform the lives of millions of people affected by this condition. pathology.

The treatment in question, ubrogepant, is an inhibitor of calcitonin gene-related peptide (CGRP), a key player in the migraine process. According to a study published in Neurologyadministering ubrogepant at the onset of prodromal signs may prevent the crisis from developing.

Ubrogepant demonstrated significant efficacy in reducing activity limitations and improving patient satisfaction compared to placebo. Treated individuals were significantly more functional 24 hours after administration of the medicineThis discovery is all the more significant because it addresses the phase prodromal of the migraineoften overlooked. Warning signs, such as increased sensitivity to light and to noisefatigue or dizziness, appear before the pain migraine itself. The study involved 518 participants, all of whom were able to identify early symptoms of their attacks. The results showed that those taking ubrogepant were 73% more likely to report that they had “no disability” two hours after dosing, compared with the placebo group. In addition, eight hours after dosing, participants taking ubrogepant were more likely to feel “satisfied” or “very satisfied” with the treatment.

This suggests that ubrogepant not only prevents seizures but also helps maintain a normal quality of life during the prodromal phase. However, this study also raises questions about the long-term effectiveness of ubrogepant. The researchers stress the importance of conducting additional clinical trials to verify the validity of these results in larger and more diverse conditions.

Early treatment of migraines could revolutionize the management of this condition. Currently, medications are often taken once headaches have set in, which limits their effectiveness. Ubrogepant could therefore offer a new strategy to control attacks from the start.

However, despite the promising results, further research is still essential to assess the potential side effects and sustainability of this approach. Presumably, millions of migraine sufferers must be waiting with bated breath to see if this new therapy could indeed transform their daily lives.